This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

Kieran Gallahue Biography and Net Worth

Director of Edwards Lifesciences

Kieran Gallahue is the former chairman and chief executive officer of CareFusion (NYSE: CFN) from 2011 until its acquisition by Becton Dickinson (NYSE: BDX) in 2015 for $12.3 billion. Kieran is currently a director on the boards of public companies: Edwards Lifesciences Corp. (NYSE: EW), Intersect ENT (NASDAQ: XENT) and Arena Pharmaceutical (NASDAQ: ARNA), and private companies: Systems Oncology and Nucleus Biologics. Prior, Kieran served on the Executive Committee of The Advanced Medical Technology Association (AdvaMed), a trade association representing 80 percent of medical technology firms in the United States. He has served as both the Chairman of the International Business Committee and as AdvaMed’s Treasurer. In addition, Kieran served on Qualcomm Life’s advisory board prior to its divestiture, and on the board of directors of Volcano Corp. (NASDAQ: VOLC), a developer of products for interventional cardiology and image-guided therapy, from 2007 until its acquisition by Philips in 2015 for $1.3 billion Qualcomm Life’s advisory board. Previously, Kieran served as president, CEO and a director of ResMed (NYSE: RMD), a medical device firm serving the sleep-disordered breathing and respiratory markets. Prior to joining ResMed, Kieran held positions at Nanogen, Instrumentation Laboratory, The Procter & Gamble Company and GE. Kieran holds a bachelor’s degree in economics from Rutgers University and an MBA from Harvard Business School.

What is Kieran Gallahue's net worth?: The estimated net worth of Kieran Gallahue is at least $5.93 million as of February 23rd, 2024. Mr. Gallahue owns 67,219 shares of Edwards Lifesciences stock worth more than $5,929,388 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Gallahue may own. Learn More about Kieran Gallahue's net worth.
How do I contact Kieran Gallahue?: The corporate mailing address for Mr. Gallahue and other Edwards Lifesciences executives is ONE EDWARDS WAY, IRVINE CA, 92614. Edwards Lifesciences can also be reached via phone at (949) 250-2500 and via email at [email protected]. Learn More on Kieran Gallahue's contact information.
Has Kieran Gallahue been buying or selling shares of Edwards Lifesciences?: Kieran Gallahue has not been actively trading shares of Edwards Lifesciences over the course of the past ninety days. Most recently, Kieran Gallahue sold 3,058 shares of the business's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $87.61, for a transaction totalling $267,911.38. Following the completion of the sale, the director now directly owns 67,219 shares of the company's stock, valued at $5,889,056.59. Learn More on Kieran Gallahue's trading history.
Who are Edwards Lifesciences' active insiders?: Edwards Lifesciences' insider roster includes Donald Bobo, Jr (VP), Daveen Chopra (VP), Kieran Gallahue (Director), Leslie Heisz (Director), Jean-Luc Lemercier (VP), Martha Marsh (Director), Michael Mussallem (CEO), Robert Sellers (VP), Catherine Szyman (VP), Scott Ullem (CFO), Nicholas Valeriani (Director), Huimin Wang (VP), Larry Wood (VP), and Bernard Zovighian (VP). Learn More on Edwards Lifesciences' active insiders.
Are insiders buying or selling shares of Edwards Lifesciences?: In the last year, insiders at the medical research company sold shares 60 times. They sold a total of 768,312 shares worth more than $62,771,727.15. The most recent insider tranaction occured on April, 8th when VP Jean-Luc M Lemercier sold 14,400 shares worth more than $1,329,408.00. Insiders at Edwards Lifesciences own 1.3% of the company. Learn More about insider trades at Edwards Lifesciences.
Information on this page was last updated on 4/8/2024.

Kieran Gallahue Insider Trading History at Edwards Lifesciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/23/2024	Sell	3,058	$87.61	$267,911.38	67,219
2/8/2022	Sell	32,256	$110.79	$3,573,642.24
2/3/2017	Buy	3,000	$90.10	$270,300.00	2,524
11/29/2016	Buy	3,000	$84.63	$253,890.00

Kieran Gallahue Buying and Selling Activity at Edwards Lifesciences

Edwards Lifesciences Company Overview

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Today's Range

Now: $88.01

$86.66

$88.73

50 Day Range

MA: $90.27

$84.87

$95.56

2 Week Range

Now: $88.01

$60.57

$96.12

Volume

4,166,251 shs

Average Volume

3,829,875 shs

Market Capitalization

$52.98 billion

P/E Ratio

38.27

Dividend Yield

N/A

Beta

1.05

Jim Cramer’s “The Biggest Drug Ever”

From Behind the Markets | Ad